Top

Tag: biotechnology


News

FogPharma clears another big-ticket financing for its ‘miniprotein’ pipeline

November 22, 2022

Via: Pharmaphorum

The Series D comes a little over 18 months after the six-year-old biotech’s third-round financing netted it around $107 million, taking its total raised to date north of $360 million. Ut comes just as FogPharma is preparing to start clinical […]


News

Delivering RNA Therapeutics through Silicon Stabilized Hybrid Lipid Nanoparticles

November 21, 2022

Via: GEN

Recent advances in biotechnology and genetic engineering have produced new therapeutics and treatment modalities for many diseases and created an emphasis on effectively delivering novel drugs to their target destinations. RNA-based therapeutics are poised to revolutionize treatment options for a […]


Biotech, Industry

Prime Medicine raises $175M in one of the year’s largest biotech IPOs

October 20, 2022

Via: Biopharma Dive

Plunging stock prices shook the biotech sector this year. Young companies attempting to go public found little appetite for the sky-high valuations that were common in 2020 and 2021’s bull run of IPOs. Some investors described that period as resulting […]


Biotech, Industry

The demand for nanoparticles in drug formulation is rising

October 17, 2022

Via: Biopharma Dive

Demand for nanoparticles in the biopharmaceutical industry is on the rise. Production of these tiny particles, which can protect and deliver medicines and vaccines where they need to go in the body, has been increasing since 1989. Over the last […]


Biotech, Industry

Prime Medicine becomes the next high-profile biotech to test the IPO waters

September 26, 2022

Via: Biopharma Dive

Prime’s filing represents a key test for biotech initial public offerings, which are showing some early signs of life after a prolonged slowdown. Twelve days ago, autoimmune drug developer Third Harmonic Bio provided the sector with a lift. By raising […]


Biotech, Industry

Biotechnology Gets $2 Billion Boost from the White House

September 15, 2022

Via: GEN

This week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]


Cell and Gene Therapy, Industry

Sangamo presses ahead with Fabry disease gene therapy

September 1, 2022

Via: Biopharma Dive

Sangamo Therapeutics is continuing to enroll and treat patients with a rare genetic condition called Fabry disease in an early clinical trial of a gene therapy it is developing, announcing Tuesday updated results from the first 11 study participants. Data […]


Cell and Gene Therapy, Industry

Beam details reasons for FDA hold on base editing cancer therapy

August 31, 2022

Via: Biopharma Dive

FDA officials are proceeding with caution as the gene editing field advances. In another recent example, the agency had issued a partial clinical hold to Editas Medicine before this July allowing that company to proceed with testing of a sickle […]


Mergers and Acquisitions

Biotech startup Ocean pivots from IPO to SPAC merger

August 31, 2022

Via: Biopharma Dive

Ocean Biomedical, a small Rhode Island-based biotechnology company, will go public through a SPAC merger with Aesther Healthcare Acquisition Corp, pivoting from plans to list shares through a traditional initial public offering. Ocean Biomedical focuses on oncology, infectious diseases and […]


Cell and Gene Therapy, Industry, Manufacturing, Research and Development

Forecyte Bio and Cytiva to Collaborate on Cell and Gene Therapy Manufacturing and Development

August 31, 2022

Via: Biopharm International

Cytiva and Forecyte Bio announced on August 25, 2022 that they will collaborate to accelerate the manufacturing and development of the cell and gene therapy industry in China and the United States. The companies will utilize Cytiva’s Fast Trak center […]


Cell and Gene Therapy, Industry

Applied StemCell Expands Cell and Gene Therapy Manufacturing Facility

August 31, 2022

Via: Contract Pharma

Applied StemCell, Inc. (ASC), a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, is expanding its current good manufacturing (cGMP) facility. ASC has […]


Industry, Vaccines

COVID Vaccine Won’t Raise Stroke Risk

August 30, 2022

Via: Drugs.com

COVID-19 vaccines do not increase your risk for stroke, new research shows, but severe COVID infection does, and experts hope the finding will ease the concerns of those who are hesitant to get the shot. “We now know that patients […]


Mergers and Acquisitions

Neurocrine Bio agrees $57m takeover of UK biotech Diurnal

August 30, 2022

Via: Pharmaphorum

The 27.5 pence-a-share cash deal values Diurnal at around £48.3 million ($57 million), a 144% premium to the biotech’s closing share price on Friday. Shares in the UK firm had leaped 132% to 26.1 pence at the time of writing […]


Clinical Trials, Research and Development

Psychedelic clinical trials: What sponsors should know when designing new protocols

August 29, 2022

Via: Biopharma Dive

Psychedelic products are having a renaissance moment. As evidence emerges about their potential for PTSD, depression, cancer-related distress and more, the market for psychedelics could swell from $2 billion in 2020 to $10.75 billion in 2027. With regulators and lawmakers […]


Manufacturing, Mergers and Acquisitions, Research and Development

ElevateBio and the Univ. of Pittsburgh Enter Biomanufacturing Partnership

August 26, 2022

Via: Contract Pharma

ElevateBio and the University of Pittsburgh have entered into a long-term partnership to accelerate the development of cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice (GMP) manufacturing […]


Cell and Gene Therapy, Industry

Roctavian okay sets up another gene therapy test for Europe

August 26, 2022

Via: Pharmaphorum

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein […]


Industry, Vaccines

AI-derived cancer vaccines: the pharmaphorum podcast

August 25, 2022

Via: Pharmaphorum

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. […]


Clinical Trials, Research and Development

To build diversity into clinical trials, collaborate at the community level

August 24, 2022

Via: Pharmaphorum

Removing barriers to clinical trial participation for underserved groups is an essential part of addressing health inequalities. Getting there, however, is easier said than done. The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants […]


Industry, Vaccines

Next-generation RNA technologies: making longer-lasting drugs with a broader reach

August 23, 2022

Via: Biopharma Dive

The key ingredient in the coronavirus vaccines developed by Moderna and BioNTech doesn’t last very long. Once in the body, this messenger RNA, or mRNA, degrades within days. Still, that’s enough time for the vaccines to train the body to […]


Mergers and Acquisitions

Aerie’s glaucoma drug journey ends in $770M sale to Alcon

August 23, 2022

Via: Biopharma Dive

Alcon has agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs. Alcon, the former eyecare business of Swiss pharmaceutical giant Novartis, will pay $15.25 […]